Posters

Cataract surgery in patients with pars planitis and immunosuppressive therapy

Poster Details

First Author: E.Guinto Arcos MEXICO

Co Author(s):    J. Serna-Ojeda   T. Albavera   M. Pedroza-Seres              

Abstract Details

Purpose:

To evaluate the characteristics and outcomes of cataract surgery in patients with pars planitis who received immunosuppressive therapy

Setting:

A reference ophthalmology center in Mexico City

Methods:

We reviewed 374 electronic records of patients with diagnosis of pars planitis between January 2003 and November 2014. Patients that received immunosuppressive therapy selected. Among those patients only those who underwent cataract surgery were included. A retrospective analysis was performed, and the following data were collected: age at presentation, age at cataract surgery, follow-up, and visual acuity before surgery, at 1 week, at 1 month and 6 months after the surgery, inflammation after the surgery, immunosuppressive therapy used, surgical and postoperative complications and causes for failure of visual improvement.

Results:

Sixteen eyes were included. Median age at presentation10.5 years. Patients showed no signs of inflammation before surgery for at least 2 months. Immunosuppressive therapy used was methotrexate in 15 patients, azathioprine in 6, and combined therapy in 5 patients. Thirteen patients received immunosuppressive therapy for an average of 8 months before surgery, 3 patients received systemic steroids before surgery and immunosuppressors after surgery. Fifteen patients (93.7%) underwent phacoemulsification with intraocular lens implantation in the capsular bag, 9 patients (56.2%) required anterior vitrectomy. Visual acuity improved from 20/800 to 20/100 after 6 months follow up; 14 patients (87.5%) improved two lines of vision or more. Median follow up after surgery was 32 months.

Conclusions:

Phacoemulsification was the elective procedure for all the patients in this study with a high rate of anterior vitrectomy. Visual acuity improved in patients with pars planitis treated with immunosuppressive drugs who underwent cataract surgery, except for the patients with clinical manifestations or amblyopia or posterior segment pathology.

Financial Disclosure:

NONE